Glaukos (GKOS) Stock

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), a company that develops innovative treatments for glaucoma, corneal issues, and retinal diseases, is set to announce its financial results for the fourth quarter and the entire year of 2024 after the market closes on Thursday, February 20, 2025. The management team will hold a conference call and a live webcast to discuss these results at 1:30 p.m. PT (4:30 p.m. ET) on the same day.

GKOS is still seeing strong demand for its products and is growing in new markets. There is a promising development pipeline that brings hope for the future.

Investors feel positive about GKOS because of its strong range of products and the high demand for them, as well as its growth into new markets.

GKOS has submitted a New Drug Application for its Epioxa to the FDA.

Glaukos Corporation (GKOS) is set to increase its sales at an annual growth rate of around 20% until fiscal year 2027, possibly reaching $680 million in revenue and $90-$100 million in post-tax earnings. The stock is currently priced at 21 times its sales, reflecting strong growth expectations, but there is a 27% margin of safety at the current price. The company's effective asset management and solid cash flow contribute to its sustainable growth, mainly fueled by the adoption of iDose TR and iStent infinite in both domestic and international markets.

This Analyst Blog features companies like Intuitive Surgical, Globus Medical, Glaukos, Veracyte, and Inogen.

GKOS is still seeing strong demand for its products and is growing in new markets. There is a promising development pipeline that brings hope for the future.

In this article, we talk about five medical device stocks: ISRG, GMED, GKOS, VCYT, and INGN. These stocks saw growth in 2024, even with ongoing difficulties, and they present a promising investment chance for 2025.

The main figures for Glaukos (GKOS) provide an overview of the company's performance for the quarter that ended in September 2024. However, it could be useful to compare some important metrics with Wall Street predictions and the results from the same period last year.